QT Imaging’s CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon Week

Dr. Raluca Dinu Participates in High-Profile Panels and Awards Ceremony Alongside Leading Healthcare Investors and Women’s Health Experts

NOVATO, Calif.--(BUSINESS WIRE)-- QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company engaged in the research, development and commercialization of innovative body imaging systems, announces that CEO Dr. Raluca Dinu presented the Shiftmaker Award to Martina Navratilova at the Sports Shiftmaker Awards ceremony last weekend and is participating in a series of thought-provoking women’s health panels during Wimbledon week in London. The panels and ceremony are hosted by The Shift, a mission-driven, intergenerational women's media platform backed by Harvard University, Gloria Steinem, and other prominent leaders, showcasing the stories of women shaping business, culture, and society.

“The inspiring conversations taking place this week reflect a growing recognition that women’s health has entered a new era,” said Dr. Dinu. “Patients, clinicians, researchers, entrepreneurs, and investors are aligned around the need for personalized, patient-centered healthcare solutions. As innovation continues to advance, the focus must remain on ensuring these technologies are safe, can meaningfully improve patient experiences, expand access to care, and provide women with the information they need to make informed healthcare decisions.

“Martina’s story embodies so many of the themes driving progress in women's health today,” added Dr. Dinu. "As one of the most accomplished athletes in history and a breast cancer survivor, her powerful advocacy highlights the importance of empowering women with information, options, and access to innovative healthcare solutions. It was an honor to share the stage with her and other leaders who are shaping the future of women's health."

Dr. Dinu joined global leaders from healthcare, investment, academia, and advocacy to discuss the future of breast health and women’s healthcare innovation. The discussions brought together influential voices focused on advancing women’s health through innovation, investment, patient advocacy, and improved access to care.

On June 27, QT Imaging served as the presenting partner for the Shiftmaker Award honoring Navratilova, whose record 59 Grand Slam titles and decades of leadership in women's sports have inspired generations of women worldwide. Following diagnoses for breast and throat cancer, Navratilova has become a prominent advocate for breast health awareness, screening and early detection. Navratilova was recognized with the Shiftmaker Award for her extraordinary achievements in sport and her ongoing advocacy for women's health, resilience and empowerment.

Following the award ceremony on June 27 tennis legend and two-time cancer survivor Martina Navratilova, biotech investor Kriti Lall of Perceptive Advisors, and award-winning journalist Sophia Li joined Dr. Dinu to present, “The Paradigm Shift: Redefining the Standard of Care in Women’s Health.” The discussion brought together the patient, innovation, and investment perspectives to explore how advances in breast health, early detection, and personalized care are transforming outcomes for women worldwide.

Today, Dr. Dinu will participate in “The Era of the Execution Shift for Women’s Health: Scaling Science and Access in Women’s Health,” a panel focused on leading innovation in women's health, with a focus on breast cancer. The panel features biotech investor Susan Wang of T. Rowe Price, Caroline Jefferies of the Center for Research in Women’s Health, and Jaya Rosenmeir, Global Head of Clinical at Novartis. It is being moderated by a journalist from ELLE UK.

Throughout the forums, panelists discussed how the convergence of patient advocacy, technological innovation, scientific research, and investment capital is driving meaningful progress in women’s health. Discussions also highlighted the increasing focus on breast health, breast density awareness, personalized screening approaches, and the importance of improving the patient experience throughout the continuum of care.

QT Imaging’s participation underscores its commitment to advancing breast health through innovative imaging technologies that provide clinicians and patients with additional quantitative information and support a more comfortable patient experience. The Company’s involvement in the forums also aligns with its broader mission to help shape the future of breast health through technologies that support more personalized, patient-centered approaches to care.

About QT Imaging

QT Imaging Holdings, Inc. (Nasdaq: QTI) is a medical device company engaged in the research, development, and commercialization of innovative imaging systems that use low-frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com and follow us on LinkedIn.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the repeatability and reproducibility metrics for quantitative biomarkers generated by the QT Imaging Breast Acoustic CT Scanner, and what that means for its commercialization, advanced image reconstruction software performance of software enhancements, plans for QT Imaging, new product development and introduction, product sales growth and projected revenues, QT Imaging’s industry, future events, and other statements that are not historical facts. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of QT Imaging's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by you or any other investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the Company to sell and deploy the QT Imaging Breast Acoustic CT™ Scanner; the ability to extend product offerings into new areas or products; the ability to commercialize technology; unexpected occurrences that deter the full documentation and “bring to market” plan for products; trends and fluctuations in the industry; changes in demand and purchasing volume of customers; unpredictability of suppliers; the ability to attract and retain qualified personnel and the ability to move product sales to production levels; changes in domestic and foreign business, market, financial, political, and legal conditions; the uncertainty of projected financial information; delays caused by factors outside of our control; changes in our ability to successfully receive purchase orders and generate revenue under our existing contracts with partners and distributors; our ability to realize the benefits of the strategic partnerships; the identified material weakness in our internal controls over financial reporting (including the timeline to remediate the material weakness); the rollout of the business and the timing of expected business milestones; the effects of competition on our future business; our ability to obtain and access financing in the future; our ability to pay our debt obligations as they come due; and those factors discussed in the Company’s reports and other documents filed with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging presently does not know or that QT Imaging currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging's expectations, plans or forecasts of future events and views as of the date of this release. QT Imaging anticipates that subsequent events and developments will cause QT Imaging's assessments to change. However, while QT Imaging may elect to update these forward-looking statements at some point in the future, QT Imaging specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Investors
CORE IR
Tirth Patel
ir@qtimaging.com
386-295-2215

Media
CORE IR
Matthew Cossel
pr@qtimaging.com
212-655-0924

Source: QT Imaging Holdings, Inc.

Released June 29, 2026